Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

References

• Hochhaus A, O’Brien SG, Guilhot F, et al. Six year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–1061. doi: 10.1038/leu.2009.38
   PubMed Web of Science ®Google Scholar
• O’Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure or chronic myeloid leukemia. Blood. 2007;110(7):2242–2249. doi: 10.1182/blood-2007-03-066936
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. doi: 10.1182/blood-2013-05-501569
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303–2309. doi: 10.1182/blood-2006-09-047266
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540–3546. doi: 10.1182/blood-2007-03-080689
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl J Med. 2006;354(24):2531–2541. doi: 10.1056/NEJMoa055229
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New Engl J Med. 2006;354(24):2542–2551. doi: 10.1056/NEJMoa055104
   PubMed Web of Science ®Google Scholar
• Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208–1215. doi: 10.1182/blood-2010-12-326405
   PubMed Web of Science ®Google Scholar
• Carneiro BA, Kaplan JB, Giles FJ. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events. Expert Rev Hematol. 2015;8(4):457–479. doi: 10.1586/17474086.2015.1041910
   PubMed Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Fogli M, et al. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Rev Hematol. 2013;6(5):563–574. doi: 10.1586/17474086.2013.837279
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;109(2):497–499. doi: 10.1182/blood-2006-07-035493
   PubMed Web of Science ®Google Scholar
• Garg RJ, Kantarjian H, O’Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114(20):4361–4368. doi: 10.1182/blood-2009-05-221531
   PubMed Web of Science ®Google Scholar
• Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116(25):5497–5500. doi: 10.1182/blood-2010-06-291922
   PubMed Web of Science ®Google Scholar
• Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010;24(7):1299–1301. doi: 10.1038/leu.2010.110
   PubMed Web of Science ®Google Scholar
• Russo Rossi A, Breccia M, Abruzzese E, et al. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica. 2013;98(3):399–403. doi: 10.3324/haematol.2012.064337
   PubMed Web of Science ®Google Scholar
• Ribeiro BF, Miranda EC, de Albuquerque DM, et al. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. Clinics (Sao Paulo). 2015;70(8):550–555. doi: 10.6061/clinics/2015(08)04
   PubMed Web of Science ®Google Scholar
• Lomaia E, Zaritskey A, Shuvaev V, et al. Efficacy of tyrosine kinase inhibitors in third line therapy in chronic phase chronic myeloid leukemia. Blood. 2015;126(23):4051. [abstract]
   Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–6051. doi: 10.1200/JCO.2009.25.0779
   PubMed Web of Science ®Google Scholar
• Erbilgin Y, Catal S, Eskazan AE, et al. ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method. Turk J Hematol. 2011;28(2):97–102. doi: 10.5152/tjh.2011.24
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Melo JV, Baccarani M, et al. Chronic myelogenous leukemia BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 32–37.
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi: 10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417. doi: 10.1056/NEJMoa062867
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567–4576. doi: 10.1182/blood-2011-05-355594
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075–2088. doi: 10.1056/NEJMoa1205127
   PubMed Web of Science ®Google Scholar